Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
NVAX
Strong SellNovavax, Inc. · Healthcare · United States · $1.5B · Avg Vol: $37M/d
COMPANY DESCRIPTION
Novavax, Inc. is a biotechnology company focused on developing and commercializing innovative vaccines to address serious infectious diseases, prominently known for its protein-based COVID-19 vaccine. The company's competitive advantage lies in its proprietary recombinant nanoparticle technology and Matrix-M adjuvant, enabling the creation of highly effective and stable vaccine candidates.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.6B | 556.4M | 682.2M | 1.1B | -11.1% | 413.8M | 372.9M | 266.2M | -51.3% |
| EPS | -8.42 | -5.41 | -1.23 | 2.72 | — | -1.53 | -0.47 | -0.25 | — |
| Shares | 86.0M | 139.5M | 160.4M | 162.6M | +89.0% | 164.9M | — | — | — |
| Debt | 549.8M | 229.1M | 230.4M | 248.8M | -23.2% | 297.3M | — | — | — |
| Equity | -634.1M | -716.9M | -623.8M | -127.8M | — | — | — | — | — |
| Op CF | -415.9M | -714.0M | -87.3M | -244.6M | — | -36.9M | — | — | — |
| Inv CF | -93.0M | -58.8M | -204.0M | -78.3M | — | — | — | — | — |
| Fin CF | 325.0M | 4.5M | 260.6M | 27.7M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of NVAX are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| NVAX | Novavax, Inc.(you) | $1.5B | 16 | Strong Sell |
| ABSI | Absci Corporation | $1.5B | 18 | Strong Sell |
| INBX | Inhibrx Biosciences, Inc. | $1.8B | 16 | Strong Sell |
| TSHA | Taysha Gene Therapies, Inc. | $1.9B | 17 | Strong Sell |
| AVLN | Avalyn Pharma Inc. | $1.5B | 11 | Strong Sell |
| STOK | Stoke Therapeutics, Inc. | $2.0B | 16 | Strong Sell |
| AKTS | Aktis Oncology, Inc. | $1.4B | 12 | Strong Sell |
| TYRA | Tyra Biosciences, Inc. | $1.5B | 10 | Strong Sell |
| RXRX | Recursion Pharmaceuticals, Inc. | $1.8B | 13 | Strong Sell |
| DMRA | Damora Therapeutics, Inc. | $1.8B | 20 | Sell |
Peer medians: ROE -25.8% · P/E 29.5x · Gross margin 58.7%